Neuroinflammation mediated by microglia and infiltrating peripheral immune cells is a major component of stroke pathophysiology. The calcium activated potassium channel K.sub.Ca3.1 is expressed selectively in the injured CNS by microglia, and K.sub.Ca3.1 function has been implicated in proinflammatory activation of microglia. K.sub.Ca3.1 is further implicated in the pathophysiology of ischemia/reperfusion (stroke) related brain injury. Senicapoc, an investigational drug with a proven safety profile and shown to cross the blood-brain barrier, is a potent and selective K.sub.Ca3.1 inhibitor that intervenes in the inflammation cascade that follows ischemia/reperfusion, and is a potential treatment for stroke.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection. The compositions may be administered intact, or may be crushed prior to administration.

This disclosure provides cannabinoid preparations for human consumption that have proven clinical benefits in patients infected with SARS-CoV-2 (the virus that causes COVID-19). The preparations are made from full-spectrum hemp oil, which includes a mixture of cannabinoids that work synergistically. The hemp oil is micellized with a median particle size of 22 nm in diameter, which considerably increases intestinal absorption, resulting in higher potency and a more rapid onset of action. Taken regularly, the preparation helps improve sleep quality by lengthening the time spent in deep sleep. In patients with COVID, the improved sleep quality is accompanied by a lower risk of cytokine storm.

The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor. Specifically, the present invention relates to use of quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine in the treatment of triple-negative breast cancer, ##STR00001##

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Compositions and methods for improving gastrointestinal function and reducing the presence of gas bubbles in a gastrointestinal tract. A composition includes an effective amount of ginger root extract for reducing gas bubbles in a gastrointestinal tract and further includes propylene glycol and sodium chloride.

Pharmaceutical or food supplement preparation including alpha-lactalbumin and at least one short-chain fatty acid (SCFA) or a precursor or derivative thereof for use in the treatment of disorders of the central nervous system; the SCFA or its precursor or derivative may be contained in at least one first dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint and the alpha-lactalbumin in at least one second dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint, and said dosage units may be distinct units intended for simultaneous or separate administration or the preparation may consist of a pharmaceutical or food supplement composition comprising the at least one short-chain fatty acid or a precursor or derivative thereof and alpha-lactalbumin together with a carrier acceptable from the pharmaceutical or food standpoint.

This invention relates to a method of treating Major depressive disorder by orally administering to a subject a composition containing a Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). A solid dosage form of PDC-1421 can be prepared into the gelatin capsule. The oral administration of PDC-1421 in healthy volunteers was safe and well-tolerated for the daily dose from 380 mg to 3800 mg. The composition can be administered chronically over at least 25 days; the daily dose is administered once per day, twice per day, or three times per day, wherein each dose is 380-760 mg of the botanical extraction.

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.